Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs
- Etrasimod initiation of the Phase 2 ADVISE trial in atopic dermatitis (AD) - Multiple first- or best-in-class drug candidates, skilled leadership team and liquidity position of approximately $1.2 billion SAN DIEGO , Nov. 7, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS
- In a Human Mass Balance study, etrasimod metabolism demonstrated no major metabolites - The overall results suggest low risk for drug-drug interactions SAN DIEGO , Nov. 6, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance,
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will present at the upcoming investor conferences: Credit Suisse 28th Annual Healthcare Conference – Presenting on Tuesday, November 12 , at 10:00 AM ET (
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2019 Financial Results and Provide Corporate Update on November 7
SAN DIEGO , Oct. 31, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019 , after the close of the U.S. financial markets. The Company will host a conference call and live
View HTML
Toggle Summary Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO , Oct. 28, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week
- Most patients that experienced clinical response, clinical remission, or endoscopic improvement with etrasimod 2 mg in the Phase 2 OASIS trial observed sustained or improved effects up to week 46 of treatment - Etrasimod demonstrated a favorable safety profile, consistent with the double-blind
View HTML
Toggle Summary Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community
- New open-label extension data from the Phase 2 OASIS trial for etrasimod in ulcerative colitis - Arena sponsored breakfast symposium: Will oral therapies change the IBD treatment landscape? - Visit Arena in the exhibit hall at booth #78 SAN DIEGO , Oct.
View HTML
Toggle Summary Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting
  SAN DIEGO, Calif. , Sept. 26, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2
  SAN DIEGO , Sept. 25, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , President and Chief Executive Officer of Arena, will present a corporate update at the Cantor Global Healthcare Conference on Wednesday, October 2 , at 3:00 PM EDT .
View HTML
Toggle Summary Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting
SAN DIEGO , Sept. 17, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of immune-mediated and inflammatory
View HTML